NautaDutilh advised Mylan in its recommended public offer for pharmaceuticals company Meda. The offer consideration consists of a combination of cash and Mylan ordinary shares with a value at announcement of SEK 165 per Meda share. The total enterprise value of the offer for all Meda shares is approximately SEK 83.6 billion or USD 9.9 billion.
The offer has been unanimously recommended by Meda's board of directors. Meda's two largest shareholders, representing in the aggregate approximately 30% of Meda's outstanding shares, have undertaken to accept the offer, subject to certain conditions.
The combination of Mylan and Meda will create a diversified global pharmaceutical leader with an expansive portfolio of branded and generic medicines and a strong and growing portfolio of over-the-counter (OTC) products.
The offer is expected to be completed by the end of the third quarter of 2016.
NautaDutilh's team advising Mylan in connection with this deal is led by Leo Groothuis and Paul van der Bijl and further consisted of Paul Olden, Elizabeth van Schilfgaarde, Petra Zijp, Frans Overkleeft, Jules van de Winckel, Sven Uiterwijk, Stefan Wissing and Philip Silvis.
NautaDutilh worked alongside Cravath, Swaine & Moore as US counsel and Vinge as Swedish counsel.
Various media reported on the deal, including:
- Mylan in USD 7.2 Billion Deal for Meda, a Swedish Drug Maker (NY Times)
- Mylan to buy Swedish drugmaker Meda in $7.2 billion deal (Reuters)